Aberrant ALK fusions were recently identified in a subset of lung cancer patients, resulting in the constitutive activation of MEK/ERK and PI3K pathways, with consequent up-regulation of cell survival and proliferation mechanisms [9, 21]. Here, ALK is linked to lung cancer.